Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0002095702-25-000003
Filing Date
2025-11-12
Accepted
2025-11-12 20:34:59
Documents
1
Period of Report
2025-11-10

Document Format Files

Seq Description Document Type Size
1 form4-11132025_011155.html 4  
1 form4-11132025_011155.xml 4 3817
  Complete submission text file 0002095702-25-000003.txt   5261
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Issuer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O LYELL IMMUNOPHARMA, INC. 201 HASKINS WAY, SUITE 101 SOUTH SAN FRANCISCO CA 94080
Business Address
Bulis Veronica Sanchez (Reporting) CIK: 0002095702 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40502 | Film No.: 251475041